Glycogen synthase kinase-3β suppression eliminates tumor necrosis factor-related apoptosis-inducing ligand resistance in prostate cancer

Molecular Cancer Therapeutics

Volumn 2, Issue 11, 2003, Pages 1215-1222

  Liao, Xinbo ^a   Zhang, Liping ^b   Thrasher, J Brantley ^a   Du, Jie ^b   Li, Benyi ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS REGULATORY PROTEIN; CASP8 PROTEIN, HUMAN; CASPASE; CASPASE 8; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LITHIUM CHLORIDE; MEMBRANE PROTEIN; PYRONE DERIVATIVE; SMALL INTERFERING RNA; TNFSF10 PROTEIN, HUMAN; TRICHODION; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; ENZYMOLOGY; GENE SILENCING; GENETICS; HUMAN; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CASPASE 8; CASPASES; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE SILENCING; GLYCOGEN SYNTHASE KINASE 3; HUMANS; LITHIUM CHLORIDE; MALE; MEMBRANE GLYCOPROTEINS; NF-KAPPA B; PROSTATIC NEOPLASMS; PYRONES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 2542425324     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E., and Thun, M. J. Cancer statistics. CA Cancer J. Clin., 52: 23-47, 2002.
2. Denmeade, S. R., Lin X. S., and Isaacs J. T. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate, 28: 251-265, 1996. (Pubitemid 26119117)
3. Wajant, H., Pfizenmaier, K., and Scheurich, P. TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy. Apoptosis, 7: 449-459, 2002.
4. Srivastava, R. K. TRAIL/Apo-2L: mechanisms and clinical applications in cancer. Neoplasia, 3: 535-546, 2001. (Pubitemid 33151020)
5. Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., DeForge, L., Koumenis, I. L., Lewis, D., Harris, L., Bussiere, J., Koeppen, H., Shahrokh, Z., and Schwall, R. H. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest., 104: 155-162, 1999.
6. Walczak, H., Bouchon, A., Stahl, H., and Krammer, P. H. Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells. Cancer Res., 60: 3051-3057, 2000. (Pubitemid 30395834)
7. Nesterov, A., Ivashchenko, Y., and Kraft, A. S. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) triggers apoptosis in normal prostate epithelial cells. Oncogene, 21: 1135-1140, 2002. (Pubitemid 34174527)
8. Kim, K., Fisher, M. J., Xu, S. Q., and el-Deiry, W. S. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin. Cancer Res., 6: 335-346, 2000. (Pubitemid 30111448)
9. Nimmanapalli, R., Perkins, C. L., Orlando, M., O'Bryan, E., Nguyen, D., and Bhalla, K. N. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res., 61: 759-763, 2001. (Pubitemid 32128643)
10. Munshi, A., McDonnell, T. J., and Meyn, R. E. Chemotherapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells. Cancer Chemother. Pharmacol., 50: 46-52, 2002. (Pubitemid 34743995)
11. Wu, X. X., Kakehi, Y., Mizutani, Y., Kamoto, T., Kinoshita, H., Isogawa, Y., Terachi, T., and Ogawa, O. Doxorubicin enhances TRAIL-induced apoptosis in prostate cancer. Int. J. Oncol., 20: 949-954, 2002.
12. Voelkel-Johnson, C., King, D. L., and Norris, J. S. Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. Cancer Gene Ther., 9: 164-172, 2002. (Pubitemid 34141919)
13. Zisman, A., Ng, C. P., Pantuck, A. J., Bonavida, B., and Belldegrun, A. S. Actinomycin D and gemcitabine synergistically sensitize androgen-independent prostate cancer cells to Apo2L/TRAIL-mediated apoptosis. J. Immunother., 24: 459-471, 2001. (Pubitemid 33104865)
14. Woodgett, J. R. Judging a protein by more than its name: GSK-3. Sci. STKE, 100: RE12, 2001.
15. Schwabe, R. F. and Brenner, D. A. Role of glycogen synthase kinase-3 in TNF-α-induced NF-κB activation and apoptosis in hepatocytes. Am. J. Physiol. Gastrointest. Liver Physiol., 283: G204-G211, 2002. (Pubitemid 34666179)
16. Hoeflich, K. P., Luo, J., Rubie, E. A., Tsao, M. S., Jin, O., and Woodgett, J. R. Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation. Nature, 406: 86-90, 2000. (Pubitemid 30460216)
17. Sridhar, S., Ali, A. A., Liang, Y., El Etreby, M. F., Lewis, R. W., and Kumar, M. V. Differential expression of members of the tumor necrosis factor α-related apoptosis-inducing ligand pathway in prostate cancer cells. Cancer Res., 61: 7179-7183, 2001. (Pubitemid 32946512)
18. Li, B. and Dou Q. P. Bax degradation by the ubiquitin/proteasome- dependent pathway: involvement in tumor survival and progression. Proc. Natl. Acad. Sci. USA, 97: 3850-3855, 2000. (Pubitemid 30226050)
19. Liao, X., Thrasher, J. B., Pelling, J., Sang, Q. X., Holzbeierlien, J., and Li, B. Androgen stimulates matrix metalloproteinase 2 expression in human prostate cancer. Endocrinology, 144: 1656-1663, 2003. (Pubitemid 36543300)
20. Schotte, P., Van Loo, G., Carpentier, I., Vandenabeele, P., and Beyaert, R. Lithium sensitizes tumor cells in an NF-κB-independent way to caspase activation and apoptosis induced by tumor necrosis factor (TNF). Evidence for a role of the TNF receptor-associated death domain protein. J. Biol. Chem., 276: 25939-25945, 2001.
21. Beyaert, R., Heyninck, K., De Valck, D., Boeykens, F., van Roy, F., and Fiers, W. Enhancement of tumor necrosis factor cytotoxicity by lithium chloride is associated with increased inositol phosphate accumulation. J. Immunol., 151: 291-300, 1993. (Pubitemid 23206994)
22. Klein, P. S. and Melton, D. A. A molecular mechanism for the effect of lithium on development. Proc. Natl. Acad. Sci. USA, 93: 8455-8459, 1996. (Pubitemid 26269579)
23. Stambolic, V., Ruel, L., and Woodgett, J. R. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signaling in intact cells. Curr. Biol., 6: 1664-1668, 1996. (Pubitemid 27050234)
24. Davies, S. P., Reddy, H., Caivano, M., and Cohen, P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J., 351: 95-105, 2000.
25. Coghlan, M. P., Culbert, A. A., Cross, D. A., Corcoran, S. L., Yates, J. W., Pearce, N. J., Rausch, O. L., Murphy, G. J., Carter, P. S., Roxbee, Cox, L., Mills, D., Brown, M. J., Haigh, D., Ward, R. W., Smith, D. G., Murray, K. J., Reith, A. D., and Holder, J. C. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem. Biol., 7: 793-803, 2000.
26. McManus, M. T. and Sharp, P. A. Gene silencing in mammals by small interfering RNAs. Nat. Rev. Genet., 3: 737-747, 2002.
27. Katsuoka, Y., Hoshino, H., Shiramizu, M., Sakabe, K., and Seiki, K. Autoradiographic and cytochemical localization of androgen in human prostatic cancer cell lines. Urology, 28: 228-231, 1986. (Pubitemid 17063393)
28. Hughes, K., Nikolakaki, E., Plyte, S. E., Totty, N. F., and Woodgett, J. R. Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation. EMBO J., 12: 803-808, 1993. (Pubitemid 23073729)
29. LeBlanc, H. N. and Ashkenazi, A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ., 10: 66-75, 2003. (Pubitemid 36511833)
30. Luo, X., Budihardjo, I., Zou, H., Slaughter, C., and Wang, X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell, 94: 481-490, 1998. (Pubitemid 28391864)
31. Martin, D. A., Siegel, R. M., Zheng, L., and Lenardo, M. J. Membrane oligomerization and cleavage activates the caspase-8 (FLICE/MACHα1) death signal. J. Biol. Chem., 273: 4345-4349, 1998. (Pubitemid 28103169)
32. Schneider, P., Thome, M., Burns, K., Bodmer, J. L., Hofmann, K., Kataoka, T., Holler, N., and Tschopp, J. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-κB. Immunity, 7: 831-836, 1997. (Pubitemid 28064896)
33. Ravi, R., Bedi, G. C., Engstrom, L. W., Zeng, Q., Mookerjee, B., Gelinas, C., Fuchs, E. J., and Bedi, A. Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-κB. Nat. Cell Biol., 3: 409-416, 2001. (Pubitemid 32288449)
34. Nemeth, Z. H., Deitch, E. A., Szabo, C., Fekete, Z., Hauser, C. J., and Hasko, G. Lithium induces NF-κB activation and interleukin-8 production in human intestinal epithelial cells. J. Biol. Chem., 277: 7713-7719, 2002. (Pubitemid 34968217)
35. Harper, N., Farrow, S. N., Kaptein, A., Cohen, G. M., and MacFarlane, M. Modulation of tumor necrosis factor apoptosis-inducing ligand-induced NF-κB activation by inhibition of apical caspases. J. Biol. Chem., 276: 34743-34752, 2001.
36. Shirakawa, F. and Mizel, S. B. In vitro activation and nuclear translocation of NF-κB catalyzed by cyclic AMP-dependent protein kinase and protein kinase C. Mol. Cell. Biol., 9: 2424-2430, 1989. (Pubitemid 19148123)
37. Kimura, K. and Gelmann, E. P. Propapoptotic effects of NF-κB in LNCaP prostate cancer cells lead to serine protease activation. Cell Death Differ., 9: 972-980, 2002. (Pubitemid 35023612)
38. Erkel, G. Trichodion, a new inhibitor of inflammatory signal transduction pathways from a Trichosporiella species. FEBS Lett., 477: 219-223, 2000. (Pubitemid 30450170)
39. Kandasamy, K. and Srivastava, R. K. Role of the phosphatidylinositol 3′-kinase/PTEN/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells. Cancer Res., 62: 4929-4937, 2002. (Pubitemid 34984416)
40. Yuan, X. J. and Whang, Y. E. PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathway. Oncogene, 21: 319-327, 2002. (Pubitemid 34102140)
41. Chen, X., Thakkar, H., Tyan, F., Gim, S., Robinson, H., Lee, C., Pandey, S. K., Nwokorie, C., Onwudiwe, N., and Srivastava, R. K. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene, 20: 6073-6083, 2001. (Pubitemid 32955050)
42. Nesterov, A., Lu, X., Johnson, M., Miller, G. J., Ivashchenko, Y., and Kraft, A. S. Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J. Biol. Chem., 276: 10767-10774, 2001. (Pubitemid 38089250)
43. Munshi, A., Pappas, G., Honda, T., McDonnell, T. J., Younes, A., Li, Y., and Meyn, R. E. TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2. Oncogene, 20: 3757-3765, 2001. (Pubitemid 32646186)
44. Cross, D. A., Alessi, D. R., Cohen, P., Andjelkovich, M., and Hemmings, B. A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature, 378: 785-789, 1995. (Pubitemid 26004411)
45. Rokhlin, O. W., Bishop, G. A., Hostager, B. S., Waldschmidt, T. J., Sidorenko, S. P., Pavloff, N., Kiefer, M. C., Umansky, S. R., Glover, R. A., and Cohen M. B. Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res., 57: 1758-1768, 1997. (Pubitemid 27199671)
46. Mao, C. D., Hoang, P., and DiCorleto, P. E. Lithium inhibits cell cycle progression and induces stabilization of p53 in bovine aortic endothelial cells. J. Biol. Chem., 276: 26180-26188, 2001.
47. Cade, J. F. Recent advances in the use of lithium. Aust. NZ J. Psychiatry, 5: 3-4, 1971.